Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma

被引:30
|
作者
Uehara, M
Sano, K
Wang, ZL
Sekine, J
Ikeda, H
Inokuchi, T
机构
[1] Nagasaki Univ, Sch Dent, Dept Oral & Maxillofacial Surg 2, Nagasaki 8528588, Japan
[2] Fukui Med Univ, Dept Oral & Maxillofacial Surg, Fukui, Japan
关键词
photodynamic therapy; OK-432; biological response modifier; combined therapy; in vivo;
D O I
10.1007/s002620000134
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biological response modifier antitumor effects are enhanced by the activation of the host defense mechanisms. We have investigated the antitumor effect of photodynamic therapy (PDT) and/or local administration of a biological response modifier, the streptococcal preparation OK-432, on transplanted NR-S1 mouse squamous cell carcinoma. Hematoporphyrin oligomers (20 mg/kg body weight) were used to photosensitize PDT. A pulsed Nd:YAG dye laser, tuned at 630 nm, was used as the light source. The laser power was 15 mJ cm(-2) pulse(-1), and the irradiation time was 40 min. The photosensitizer was injected intraperitoneally 48 h before laser-irradiation. Where used, OK-432 was injected into the tumor either 3 h prior to PDT or immediately afterwards. The antitumor effects were evaluated 48 h after each protocol by (a) estimating the area of tumor necrosis(%) in hematoxylin/eosin-stained specimens, and (b) bromodeoxyuridine immunohistochemistry. Furthermore, the tumor sizes were evaluated 3, 7 and 10 days after each protocol, and the survival time after each protocol was evaluated as well. The antitumor effect of PDT was enhanced by administration of OK-432 3 h before PDT, whereas the administration of OK-432 immediately after PDT did not potentiate a PDT antitumor effect. Treatment with OK-432 alone had little effect on tumors. Photodynamic therapy in combination with local administration of OK-432 3 h before PDT is considered to be a useful treatment modality.
引用
收藏
页码:401 / 409
页数:9
相关论文
共 50 条
  • [41] PURIFICATION AND BIOLOGICAL-ACTIVITIES OF A MOUSE SERUM-PROTEIN INCREASED BY ADMINISTRATION OF STREPTOCOCCAL PREPARATION, OK-432
    TORIKAI, T
    ITOH, O
    TOYOSHIMA, S
    OSAWA, T
    GANN, 1978, 69 (05): : 657 - 665
  • [42] STUDIES ON HOST-MEDIATED ACTION OF STREPTOCOCCAL PREPARATION, OK-432, IN CANCER CHEMOTHERAPY
    KIMURA, I
    ONOSHI, T
    YASUHARA, S
    WATANABE, T
    SUGIYAMA, M
    HIRAKI, K
    ACTA MEDICA OKAYAMA, 1974, 28 (06) : 423 - 431
  • [43] BLASTOGENIC RESPONSES OF HUMAN-LYMPHOCYTES TO A STREPTOCOCCAL PREPARATION OK-432 AND ITS FRACTIONS
    TANAKA, T
    KANEKO, Y
    HABA, F
    KATSUTA, S
    TSUTSUI, K
    TAMAKI, S
    CHEN, DR
    SUZUKI, S
    UEDA, R
    YAMAMOTO, A
    JOURNAL OF CLINICAL & LABORATORY IMMUNOLOGY, 1989, 28 (02) : 91 - 96
  • [44] CLINICAL-EVALUATION OF IMMUNOCHEMOTHERAPY WITH STREPTOCOCCAL PREPARATION OK-432 ON INOPERABLE ADVANCED CANCERS
    NIO, Y
    NITTA, N
    TANAKA, A
    ICHIKAWA, T
    HENMI, K
    ARCHIV FUR JAPANISCHE CHIRURGIE, 1981, 50 (05): : 704 - 710
  • [45] CELL-MEDIATED ANTIHERPETIC ACTIVITY OF A STREPTOCOCCAL PREPARATION (OK-432) IN IMMUNOCOMPROMISED HOSTS
    IKEDA, S
    SAI, K
    NISHIMURA, C
    YAMAMOTO, A
    ANTIVIRAL RESEARCH, 1988, 9 (1-2) : 136 - 136
  • [46] IMMUNOTHERAPY USING THE STREPTOCOCCAL PREPARATION OK-432 FOR THE TREATMENT OF UTERINE CERVICAL-CANCER
    NODA, K
    TESHIMA, K
    TEKEUTI, K
    HASEGAWA, K
    INOUE, KY
    YAMASHITA, K
    SAWARAGI, I
    NAKAJIMA, T
    TAKASHIMA, E
    IKEUCHI, M
    SEKIBA, K
    OKUDA, H
    ICHIJO, M
    SAITO, T
    OZAWA, M
    TAMURA, H
    CHIHARA, T
    KUZUYA, K
    OZAKI, M
    INAGAKI, M
    TOMINAGA, S
    GYNECOLOGIC ONCOLOGY, 1989, 35 (03) : 367 - 372
  • [47] CYTOKINE-GENE-MODIFIED TUMOR VACCINATION INTENSIFIED BY A STREPTOCOCCAL PREPARATION OK-432
    ABE, J
    WAKIMOTO, H
    AOYAGI, M
    HIRAKAWA, K
    HAMADA, H
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (02) : 82 - 86
  • [49] CLINICAL EXPERIENCES WITH STREPTOCOCCAL ANTICANCER PREPARATION, OK-432 (NSC-B116209)
    KUROKAWA, T
    FURUE, H
    HATTORI, T
    CANCER CHEMOTHERAPY REPORTS PART 1, 1972, 56 (02): : 211 - &
  • [50] CLINICAL-VALUE OF IMMUNOTHERAPY FOR LUNG-CANCER BY THE STREPTOCOCCAL PREPARATION OK-432
    WATANABE, Y
    IWA, T
    CANCER, 1984, 53 (02) : 248 - 253